News
Please, enter cell line, author or any other phrase or word you would like to search for.
European Patent Office intends to grant PHI patent on synthetic antibodies
PHI AB announces today that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies.
BioStock: PHI’s CEO reflects on global roadshow success
BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
Interim Report 4 2022/23
Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.
Notice that Interim Report 4 2022/23 will be published on June 26, 2023
PHI changes the date for publication of Interim Report 4 2022/23 to June 26, 2023.
PHI’s new HoloMonitor M4FL premiers at major scientific conferences
PHI introduces the HoloMonitor M4FL system to the global scientific community at two major scientific conferences this June.
PHI AB’s warrant exercise registered with the Swedish Companies Registration Office
PHI today announces that the new shares from the exercise of warrants of series TO 3 have been registered with the Swedish Companies Registration Office.
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on 9 May 2023. The following resolutions were passed at the meeting:
TO 3 Warrants Subscribed to 100 %
On 2 May 2023, the exercise period for warrants of series TO 3, which were issued in connection with PHI AB’s rights issue of units that were announced on 22 February 2022, ended. […] The proceeds of the TO 3 warrants amount to approximately SEK 12.7 million before the deduction of transaction-related costs, corresponding to a subscription rate of 100 percent.
BioStock: PHI on how TO 3 proceeds will be used
BioStock talked to CEO Patrik Eschricht to learn how the TO 3 proceeds would be used.
Last day of trading in warrants of series TO 3 is 27 April 2023
Thursday, 27 April 2023, is the last day of trading in warrants of series TO 3, which were issued in connection with PHI’s rights issue of units that was announced on 22 February 2022. The exercise period runs until and including 2 May 2023.